

PROVIDER QUICK POINTS

PROVIDER INFORMATION



June 12, 2019

Pharmacy Benefit Exclusion for Zolgensma[®] (onasemnogene abeparvovec-xioi) Injection

Zolgensma[®] (onasemnogene abeparvovec-XIOI) injection is a new drug product approved to treat spinal muscular atrophy (SMA) in children 2 years of age and younger and was approved on May 24, 2019. When available in the marketplace, Zolgensma[®] (onasemnogene abeparvovec-xioi) will be excluded from pharmacy benefit coverage due to its clinician-administered route of administration. Zolgensma[®] (onasemnogene abeparvovec-xioi) may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Zolgensma [®] (onasemnogene abeparvovec-XIOI) injection

Products Impacted

This exclusion applies to commercial lines of business and the following Minnesota Health Care Programs.

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.

QP58-19

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Blue Cross[®] and Blue Shield[®] of Minnesota and Blue Plus[®] are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

L264R03 (12/13)